Related Experiment Video
Updated: Mar 2, 2026

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer
Aleksandra Sokolowska-Wedzina1, Grzegorz Chodaczek2, Julia Chudzian1
1Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, Wroclaw, Poland.
Abstract:
Targeted delivery of anticancer drugs using antibodies specific for tumor-associated antigens represents one of the most important approaches in current immuno-oncology research. Fibroblast growth factor receptor 1 (FGFR1) has been demonstrated to be a high-frequency targetable oncogene specific for smoking-associated lung cancers, present in over 20% of lung squamous cell carcinoma cases. This report describes the generation of a potent, fully human antibody fragment in scFv-Fc format efficiently targeting FGFR1. Antibody phage display was used to select high-affinity scFv antibody fragments against the extracellular domain of FGFR1(IIIc). Enzyme immunoassay (ELISA) and surface plasmon resonance (SPR) analysis were used for antibody screening and characterization. The best binder (named D2) was cloned to diabody and Fc fusion formats. All D2 antibodies demonstrated high affinity for FGFR1 with dissociation constants of 18 nmol/L (scFvD2), 0.82 nmol/L (scFvD2 diabody), and 0.59 nmol/L (scFvD2-Fc). scFvD2 was found to be exquisitely selective for FGFR1 versus other FGFR family members and bound FGFR1 even in the presence of its natural ligand FGF2, as shown by competitive analysis. Confocal microscopy revealed that scFvD2-Fc was specifically and rapidly internalized by a panel of cell lines overexpressing FGFR1. Finally, it was demonstrated that scFvD2-Fc mediated specific delivery of a cytotoxic payload into lung cancer cells harboring oncogenic FGFR1 gene amplifications.Implications: This study reports a highly specific internalizing antibody fragment that can serve as a therapeutic targeting agent for efficient delivery of cytotoxic drugs into FGFR1-positive lung cancer cells. Mol Cancer Res; 15(8); 1040-50. ©2017 AACR.
Insights
Researchers developed a novel antibody fragment targeting Fibroblast Growth Factor Receptor 1 (FGFR1) for lung cancer. This antibody delivers cytotoxic drugs specifically to FGFR1-positive cancer cells, offering a new immuno-oncology approach.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Targeted drug delivery via antibodies against tumor antigens is key in immuno-oncology.
- Fibroblast Growth Factor Receptor 1 (FGFR1) is a targetable oncogene in smoking-associated lung cancers, particularly squamous cell carcinoma.
Purpose of the Study:
- To generate a potent, fully human antibody fragment targeting FGFR1 for potential therapeutic applications.
- To characterize the antibody's affinity, specificity, and internalization in cancer cells.
Main Methods:
- Antibody phage display was used to select high-affinity single-chain variable fragments (scFv) against FGFR1.
- Enzyme immunoassay (ELISA) and surface plasmon resonance (SPR) were employed for screening and characterization.
- Confocal microscopy assessed cellular internalization, and payload delivery was tested in FGFR1-amplified lung cancer cells.
Main Results:
- A high-affinity antibody fragment (D2) targeting FGFR1 was generated, with dissociation constants as low as 0.59 nmol/L for the scFvD2-Fc format.
- The antibody demonstrated exquisite selectivity for FGFR1 over other family members and bound even in the presence of FGF2.
- The scFvD2-Fc fragment was rapidly internalized by FGFR1-overexpressing cells and delivered cytotoxic payloads effectively.
Conclusions:
- A highly specific, internalizing antibody fragment targeting FGFR1 has been developed.
- This antibody fragment shows promise as a therapeutic agent for targeted delivery of cytotoxic drugs to FGFR1-positive lung cancer cells.

![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)